Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study

The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study

“…Oseltamivir's effects on COVID-19 patients were investigated in other clinical observational studies. A retrospective cohort study found no effects with oseltamivir containing regimen on reducing the hospitalization time nor the one-month survival rate in COVID-19 patients in comparison with other therapeutic interventions ( Shokri et al, 2022 ). However, the study showed that patients on oseltamivir have higher lymphocyte count indicating a boost of the immune system and reduction of CRP indicating usefulness in the reduction of pneumonitis ( Shokri et al, 2022 ).…”

“…A retrospective cohort study found no effects with oseltamivir containing regimen on reducing the hospitalization time nor the one-month survival rate in COVID-19 patients in comparison with other therapeutic interventions ( Shokri et al, 2022 ). However, the study showed that patients on oseltamivir have higher lymphocyte count indicating a boost of the immune system and reduction of CRP indicating usefulness in the reduction of pneumonitis ( Shokri et al, 2022 ). The study lacked a robust design as it included patients treated with different antibiotics/medications in both groups and had other weaknesses such as the misspecification of important medication variables as the initiation time which could mask the response seen in other studies.…”